Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

Due to rare but major adverse reactions to the AstraZeneca adenoviral ChAdOx1-S-nCoV-19 vaccine (ChAd), German health authorities recommended adults under 60 who received one dose of ChAd, to receive a second dose of the BioNTech mRNA BNT162b2 vaccine (BNT) as a booster. Studies in the general popul...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Chang, Schönbrunn, Anne, Fischer, Dorothea, Liu, Yvonne, Hocher, Johann-Georg, Weinerth, Jutta, Klemm, Kristin, von Baehr, Volker, Krämer, Bernhard K., Elitok, Saban, Hocher, Berthold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291065/
https://www.ncbi.nlm.nih.gov/pubmed/37377957
http://dx.doi.org/10.3389/fimmu.2023.1187880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291065/
https://www.ncbi.nlm.nih.gov/pubmed/37377957
http://dx.doi.org/10.3389/fimmu.2023.1187880

Ejemplares similares